Jun Guo

10PUBLICATIONS
54CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Immunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Apr 15, 2025
First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors.

Daphne Day, Vinod Ganju, Ki Chung

|Nov 12, 2024
Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China.

Siming Li, Yanxia Shi, Haiying Dong

|May 02, 2024
Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications.

Jie Dai, Jia Jia, Fanshuang Zhang

|Nov 21, 2023
Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.

Xinan Sheng, Lin Wang, Zhisong He

|Sep 05, 2023
A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody-Drug Conjugate for Targeting Melanoma.

Jing Shi, Tao Jiao, Qian Guo

|Feb 07, 2023
Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study.

Chuanliang Cui, Yu Chen, Zhiguo Luo

Pageof 2

Frequent Collaborators

3 joint publications

Xinan Sheng

3 joint publications

Yan Kong

3 joint publications

Lili Mao

2 joint publications

Lu Si